# Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage

> **NCT06991920** · NA · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 50 (estimated)

## Conditions studied

- Adult ALL
- MPAL

## Interventions

- **DRUG:** Blinatumomab
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT06991920
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2030-04-01
- **Final completion:** 2032-04-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06991920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06991920, "Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06991920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*